FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000784384> ?p ?o ?g. }

• W2000784384 endingPage "385" @default.
• W2000784384 startingPage "385" @default.
• W2000784384 abstract "P535 Aims: The objetive of the present study is to review our experience with HCV-infected transplant recipient undergoing re-OLT for HCV graft cirrhosis, and receiving pegylated interferon and ribavirin on a prophylactic basis. Methods: Between May 1994, and March 2003 a total of 446 patients underwent OLT at our institution. 132 of these patients underwent transplantation for cirrhosis secondary to chronic HCV infection. Five consecutive patients undergoing liver retransplantation for HCV-related cirrhosis were included in the study. Protocol liver biopsies were performed yearly after retransplantation: The grade activitiy and stage fibrosis was determined by combining the histological activity index (HAI) scores for portal inflammation (0-4), lobular degeneration and necrosis (0-4), and periportal necrosis (0-10). All patients received tacrolimus, mofetil mycophenolate (MMF) and a monoclonal antibody anti-interleukin-2-receptor (Daclizumab) Prophylactic treatment with pegylated interferon-α-2b (PEG-intron) in combination with ribavirin was initiated in every patient Characteristics of Patients at Transplantation.FigureResults: After retransplantation, all five patients are alive with stable graft function after a median follow-up of 26 months (range, 15 to 33 months). No episodes of rejection were noted, and steroids were not necessary in any patient. Six months after retransplantation maintenance immunosuppression was tacrolimus monotherapy in all patients. After 20 months of treatment, none of the patients had cleared HCV RNA by PCR. However, mean serum levels declined significantly when compared with pre-retransplantation levels. For the entire group, there was a statistically significant decrease in serum biochemical indices assessed at 6 and 12 months into therapy when compared with pre-retransplantation levels (ALT at one year, 215 versus 64 IU/L; p<0.05) Our patients were highly selected according to the model proposed by Rosen, and although all five patients had developed aggressive recurrent disease leading to cirrhosis between two years after OLT, they were re-transplanted early after the first hepatic decompensation (median time, 6 months), before the development of infectious and renal complications In our study, we examine the efficacy of a Interleukin-2 receptor monoclonal antibody in combination with MMF and tacrolimus, without steroids. This strategy has been associated with a extremely low rate of acute cellular rejection episodes requiring steroids, one of the variables implicated in the outcome of posttransplant hepatitis C The most important, is that after retransplantation, all five patients are alive with stable graft function after a median follow-up of 26 months, which is encouraging compared to the severe and progressive disease observed after the initial transplantation. Conclusions: Although this study is limited by the small sample size and limited follow-up, our data suggest that the severity of HCV-related disease after retransplantation does not seem to predict that observed after the initial OLT. Better results can be obtained in selected patients, even with aggressive disease after the first OLT, receiving long-term combined therapy with pegylated interferon and ribavirin." @default.
• W2000784384 created "2016-06-24" @default.
• W2000784384 creator A5007942557 @default.
• W2000784384 creator A5027212705 @default.
• W2000784384 creator A5033610981 @default.
• W2000784384 creator A5034975999 @default.
• W2000784384 creator A5038372454 @default.
• W2000784384 creator A5067346620 @default.
• W2000784384 creator A5069454479 @default.
• W2000784384 creator A5090737900 @default.
• W2000784384 date "2004-07-01" @default.
• W2000784384 modified "2023-09-27" @default.
• W2000784384 title "RETRANSPLANTATION FOR HEPATITIS C-RELATED CIRRHOSIS UNDER LONG-TERM PEGYLATED INTERFERON THERAPY" @default.
• W2000784384 doi "https://doi.org/10.1097/00007890-200407271-01030" @default.
• W2000784384 hasPublicationYear "2004" @default.
• W2000784384 type Work @default.
• W2000784384 sameAs 2000784384 @default.
• W2000784384 citedByCount "0" @default.
• W2000784384 crossrefType "journal-article" @default.
• W2000784384 hasAuthorship W2000784384A5007942557 @default.
• W2000784384 hasAuthorship W2000784384A5027212705 @default.
• W2000784384 hasAuthorship W2000784384A5033610981 @default.
• W2000784384 hasAuthorship W2000784384A5034975999 @default.
• W2000784384 hasAuthorship W2000784384A5038372454 @default.
• W2000784384 hasAuthorship W2000784384A5067346620 @default.
• W2000784384 hasAuthorship W2000784384A5069454479 @default.
• W2000784384 hasAuthorship W2000784384A5090737900 @default.
• W2000784384 hasConcept C126322002 @default.
• W2000784384 hasConcept C141071460 @default.
• W2000784384 hasConcept C17991360 @default.
• W2000784384 hasConcept C203014093 @default.
• W2000784384 hasConcept C2522874641 @default.
• W2000784384 hasConcept C2776408679 @default.
• W2000784384 hasConcept C2776455275 @default.
• W2000784384 hasConcept C2776461080 @default.
• W2000784384 hasConcept C2777138892 @default.
• W2000784384 hasConcept C2777214474 @default.
• W2000784384 hasConcept C2779609443 @default.
• W2000784384 hasConcept C2779719350 @default.
• W2000784384 hasConcept C2780040827 @default.
• W2000784384 hasConcept C2780252810 @default.
• W2000784384 hasConcept C2909675724 @default.
• W2000784384 hasConcept C2911091166 @default.
• W2000784384 hasConcept C71924100 @default.
• W2000784384 hasConcept C90924648 @default.
• W2000784384 hasConceptScore W2000784384C126322002 @default.
• W2000784384 hasConceptScore W2000784384C141071460 @default.
• W2000784384 hasConceptScore W2000784384C17991360 @default.
• W2000784384 hasConceptScore W2000784384C203014093 @default.
• W2000784384 hasConceptScore W2000784384C2522874641 @default.
• W2000784384 hasConceptScore W2000784384C2776408679 @default.
• W2000784384 hasConceptScore W2000784384C2776455275 @default.
• W2000784384 hasConceptScore W2000784384C2776461080 @default.
• W2000784384 hasConceptScore W2000784384C2777138892 @default.
• W2000784384 hasConceptScore W2000784384C2777214474 @default.
• W2000784384 hasConceptScore W2000784384C2779609443 @default.
• W2000784384 hasConceptScore W2000784384C2779719350 @default.
• W2000784384 hasConceptScore W2000784384C2780040827 @default.
• W2000784384 hasConceptScore W2000784384C2780252810 @default.
• W2000784384 hasConceptScore W2000784384C2909675724 @default.
• W2000784384 hasConceptScore W2000784384C2911091166 @default.
• W2000784384 hasConceptScore W2000784384C71924100 @default.
• W2000784384 hasConceptScore W2000784384C90924648 @default.
• W2000784384 hasLocation W20007843841 @default.
• W2000784384 hasOpenAccess W2000784384 @default.
• W2000784384 hasPrimaryLocation W20007843841 @default.
• W2000784384 hasRelatedWork W2034228609 @default.
• W2000784384 hasRelatedWork W2034879163 @default.
• W2000784384 hasRelatedWork W2040639528 @default.
• W2000784384 hasRelatedWork W2065404554 @default.
• W2000784384 hasRelatedWork W2070447293 @default.
• W2000784384 hasRelatedWork W2087044527 @default.
• W2000784384 hasRelatedWork W2099226120 @default.
• W2000784384 hasRelatedWork W2517087858 @default.
• W2000784384 hasRelatedWork W651249740 @default.
• W2000784384 hasRelatedWork W2467456162 @default.
• W2000784384 hasVolume "78" @default.
• W2000784384 isParatext "false" @default.
• W2000784384 isRetracted "false" @default.
• W2000784384 magId "2000784384" @default.
• W2000784384 workType "article" @default.